Recent advancements in the treatment of chronic myelogenous leukemia

Michael E. O'Dwyer, Michael J. Mauro, Brian Druker

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

Original languageEnglish (US)
Pages (from-to)369-381
Number of pages13
JournalAnnual Review of Medicine
Volume53
DOIs
StatePublished - 2002

Fingerprint

bcr-abl Fusion Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells
Stem Cell Transplantation
Chromosomes
Philadelphia Chromosome
Interferons
Therapeutics
Genes
Leukemia
Stem Cells
Pharmaceutical Preparations

Keywords

  • Bcr-Abl
  • CML
  • STI571
  • Tyrosine kinase
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Cite this

Recent advancements in the treatment of chronic myelogenous leukemia. / O'Dwyer, Michael E.; Mauro, Michael J.; Druker, Brian.

In: Annual Review of Medicine, Vol. 53, 2002, p. 369-381.

Research output: Contribution to journalArticle

O'Dwyer, Michael E. ; Mauro, Michael J. ; Druker, Brian. / Recent advancements in the treatment of chronic myelogenous leukemia. In: Annual Review of Medicine. 2002 ; Vol. 53. pp. 369-381.
@article{1dfc98266983493fba7c461be95fcd68,
title = "Recent advancements in the treatment of chronic myelogenous leukemia",
abstract = "Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.",
keywords = "Bcr-Abl, CML, STI571, Tyrosine kinase, Tyrosine kinase inhibitor",
author = "O'Dwyer, {Michael E.} and Mauro, {Michael J.} and Brian Druker",
year = "2002",
doi = "10.1146/annurev.med.53.082901.103853",
language = "English (US)",
volume = "53",
pages = "369--381",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Recent advancements in the treatment of chronic myelogenous leukemia

AU - O'Dwyer, Michael E.

AU - Mauro, Michael J.

AU - Druker, Brian

PY - 2002

Y1 - 2002

N2 - Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

AB - Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

KW - Bcr-Abl

KW - CML

KW - STI571

KW - Tyrosine kinase

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0036179862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036179862&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.53.082901.103853

DO - 10.1146/annurev.med.53.082901.103853

M3 - Article

VL - 53

SP - 369

EP - 381

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -